Background: Inflammation is a key element in tumor progression, over time, persistent inflammation
causes damage to DNA and leads to cancer. The relationship between chronic inflammation and tumor development
is well established, blocking of which can help in cancer prevention and treatment in the future.
Objective: Hence, with this background, the present study aims to evaluate the anti-inflammatory and anticancer
potential of Cassia auriculata (CA) solvent fractions through in silico and in vitro means, respectively.
Methods: Generally, inflammatory mediators play a key task in chronic inflammation, following its inflection
was chosen for their interactions with nine structurally varied phytoconstituents of CA identified through GCMS.
The ethanolic extract of CA was assessed for its apoptotic effects on A549 lung cancer cells by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, JC-10 staining, DNA fragmentation assay
and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).
Results: The interactions between bioactive components and target protein revealed that important molecules
like 5,7-dihydroxy-2-[2-nethoxyphenyl]- 4H-1-Benzopyran-4-one, a flavonoid, and three other components can
bind target interleukin 1-beta associated with lung cancer. In vitro data also confirmed that the diverse active
components of CA extract might follow the intrinsic mitochondrial pathway to provoke cancer cell death.
Conclusion: Hence, these findings strongly propose that Cassia auriculata (CA) solvent fractions could be
exploited in the future to design ligands for obtaining novel leads for treating chronic inflammation linked with
lung cancer, and also the extracts of CA can be recommended as a potential agent for lung cancer chemotherapy.